148 related articles for article (PubMed ID: 21289369)
1. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib.
Dudeck O; Zeile M; Reichardt P; Pink D
Ann Oncol; 2011 Aug; 22(8):1828-33. PubMed ID: 21289369
[TBL] [Abstract][Full Text] [Related]
2. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.
Schramm N; Englhart E; Schlemmer M; Hittinger M; Übleis C; Becker CR; Reiser MF; Berger F
Eur J Radiol; 2013 Jun; 82(6):951-8. PubMed ID: 23518148
[TBL] [Abstract][Full Text] [Related]
3. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Shinagare AB; Jagannathan JP; Kurra V; Urban T; Manola J; Choy E; Demetri GD; George S; Ramaiya NH
Eur J Cancer; 2014 Mar; 50(5):981-6. PubMed ID: 24388774
[TBL] [Abstract][Full Text] [Related]
4. Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors.
Shinagare AB; Barysauskas CM; Braschi-Amirfarzan M; O'Neill AC; Catalano PJ; George S; Ramaiya NH
Clin Imaging; 2016; 40(5):880-4. PubMed ID: 27179958
[TBL] [Abstract][Full Text] [Related]
5. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
[TBL] [Abstract][Full Text] [Related]
6. CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria.
Meyer M; Hohenberger P; Apfaltrer P; Henzler T; Dinter DJ; Schoenberg SO; Fink C
Eur J Radiol; 2013 Jun; 82(6):923-8. PubMed ID: 23410905
[TBL] [Abstract][Full Text] [Related]
7. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
[TBL] [Abstract][Full Text] [Related]
8. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
[TBL] [Abstract][Full Text] [Related]
10. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Reichardt P; Kang YK; Rutkowski P; Schuette J; Rosen LS; Seddon B; Yalcin S; Gelderblom H; Williams CC; Fumagalli E; Biasco G; Hurwitz HI; Kaiser PE; Fly K; Matczak E; Chen L; Lechuga MJ; Demetri GD
Cancer; 2015 May; 121(9):1405-13. PubMed ID: 25641662
[TBL] [Abstract][Full Text] [Related]
12. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
13. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
Liu K; Li G; Fan C; Zhou C; Li J
Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
[TBL] [Abstract][Full Text] [Related]
14. Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'.
Kyriazoglou A; Jespers P; Vandecavaye V; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Zaffaroni F; Litière S; Nzokirantevye A; Schöffski P
Acta Oncol; 2022 Jun; 61(6):663-668. PubMed ID: 35481400
[TBL] [Abstract][Full Text] [Related]
15. Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.
Yeh CN; Wang SY; Tsai CY; Chen YY; Liu CT; Chiang KC; Chen TW; Liu YY; Yeh TS
Int J Surg; 2017 Mar; 39():30-36. PubMed ID: 28110026
[TBL] [Abstract][Full Text] [Related]
16. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
Den Hollander D; Van der Graaf WTA; Desar IME; Le Cesne A
Acta Oncol; 2019 Nov; 58(11):1648-1654. PubMed ID: 31345082
[No Abstract] [Full Text] [Related]
18. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.
Koh Y; Lee HE; Im SA; Kim SH; Kim TM; Han SW; Oh DY; Kim JH; Lee SH; Kim DW; Kim TY; Kim WH; Heo DS; Bang YJ
Diagn Mol Pathol; 2011 Sep; 20(3):143-7. PubMed ID: 21817899
[TBL] [Abstract][Full Text] [Related]
19. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
Yang W; Li K; Yu J; Shou C; Zhang Q; Hong Y; Sun J; Yu H; Gao Y; Shen Q; Zhao Z; Zheng S
Scand J Gastroenterol; 2018; 53(10-11):1328-1334. PubMed ID: 30346846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
